Henry Bence Jones – physician, chemist, scientist and biographer: A man for all seasons

  title={Henry Bence Jones – physician, chemist, scientist and biographer: A man for all seasons},
  author={Robert A. Kyle},
  journal={British Journal of Haematology},
  • R. Kyle
  • Published 1 October 2001
  • Medicine
  • British Journal of Haematology
The name Bence Jones is recognized today as the name of a protein excreted by patients with multiple myeloma. It is ironic that Bence Jones was not the first to describe the characteristics of the protein, but he recognized its place in the diagnosis of myeloma when he wrote, `I need hardly remark on the importance of seeking for this oxide of albumen in other cases of mollities ossium' (Bence Jones, 1847). J. F. Heller (1846) had described a protein in the urine that precipitated when warmed a… 
Bence Jones protein is generally accepted term for protein described in urine of myeloma patients, and is considered as the pioneer in medical chemistry and one of the first doctors who emphasized the importance of chemical analysis for the diagnosis of the disease.
Wikilite 2-A brief history of diagnostic tests for myeloma : Bence Jones protein and beyond
  • Biology
  • 2019
Dr William MacIntyre was the first person to characterise the precipitate in the urine from a patient with multiple myeloma, and his findings were reported by Henry Bence Jones in a Lancet article in
What's in a name? Bence Jones protein
Some insights are provided into the history of this commonly used eponym and its use in clinical practice and aim to put it into context.
A history of the kidney in plasma cell disorders.
Historical understanding of the kidney in plasma cell disorders reflects developments in understanding ofThe anatomy and physiology of the kidneys in health and in disease.
History of multiple myeloma.
  • R. Kyle, D. Steensma
  • Biology
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 2011
The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomice, and the recognised plasma cells and subsequently their product, a monoclonal protein.
De las células plasmáticas al mieloma múltiple. Una breve perspectiva histórica
While multiple myeloma has been known for over 100 years, much has been learned about the cell origin, its pathogenesis, molecular biology, and treatment; however, its cause is still an enigma.
Plasma cell neoplasms, their precursor States, and their prediction of organ damage.
  • R. Comenzo
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
In this landmark retrospective case-control study, Weiss et al use a serum free light chain (sFLC) assay that measures free immunoglobulin light chains, on the basis of sheep polyclonal antisera to human kappa and lambda light chains not bound to heavy chains, an assay that over the last 12 years has proven useful in the diagnosis and monitoring of patients with plasma cell neoplasms.
Monoclonal light chains and the kidney
An overview of kidney diseases in monoclonal disorders, focusing on special disease entities that primary involve glomerula or the tubulointerstitium, and the current status of treatment options of light chain cast nephropathy is summarized.
Robert Arthur Kyle, MD: A Conversation with the Editor
Dr. Robert A. Kyle, Professor of Medicine and Laboratory Medicine and Pathology at Mayo Clinic College of Medicine, Rochester, Minnesota, presented the Marvin J. Stone Lectureship, an annual lectureship at Baylor University Medical Center at Dallas, on March 23, 2010, entitled “Utilization of Risk Management of Multiple Myeloma with Novel Agents.
Review of 1027 patients with newly diagnosed multiple myeloma.
Multivariate analysis revealed that age, plasma cell labeling index, low platelet count, serum albumin value, and the log of the creatinine value were the most important prognostic factors for newly diagnosed multiple myeloma.


Henry Bence Jones: The Best Chemical Doctor in London
  • F. Putnam
  • Biology
    Perspectives in biology and medicine
  • 1993
The eponym of Bence Jones protein, the protein excreted in the urine by patients with multiple myeloma and virtually pathognomonic of this disease, is fading and is being replaced by the term light chain to signify that the protein is related to the light chains of immunoglobulins and antibodies.
Henry Bence-Jones, M. D. , F. R. S. (1813-1873)
  • N. Coley
  • Medicine
    Notes and Records of the Royal Society of London
  • 1973
The development of the subject for medical purposes became one of the main objectives of animal chemists, although from hindsight it is clear that neither the techniques nor the chemical knowledge available were at all adequate for solving the complex problems involved.
Henry Bence Jones (1813-1873): the best "chemical doctor" in London.
In September 1844, a wealthy London grocer, forty-four years of age, developed chest pains after an accidental fall, but returned a month later to persist until his death, when he was confined to his house with excruciating pain in the chest and back.
Multiple myeloma: an odyssey of discovery
  • R. Kyle
  • Medicine
    British journal of haematology
  • 2000
It is probable that 39-year-old Sarah Newbury, the second patient described by Samuel Solly (1844), had multiple myeloma, and her husband requested that she be admitted to St. Thomas' Hospital, apparently from asphyxia.
Chemical Pathology
II. On a fluorescent substance, resembling quinine, in animals; and on the rate of passage of quinine into the vascular and non- vascular textures of the body
The term fluorescence in the last few years has found a place in physiological works because different substances that occur in the body have been said to possess the property of fluorescence. Of
An Autobiography (with elucidations at later dates by his son, A
  • B. Bence-Jones). Crusha & Sons Ltd. (privately printed),
  • 1929
An Autobiography (with elucidations at later dates by his son
  • A. B. Bence-Jones). Crusha & Sons Ltd
  • 1929